KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non Operating Investment Income: 2011-2017

Historic Non Operating Investment Income for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Dec 2017 value amounting to $76,000.

  • Supernus Pharmaceuticals' Non Operating Investment Income fell 81.30% to $23,000 in Q2 2017 from the same period last year, while for Jun 2017 it was $301,000, marking a year-over-year decrease of 35.27%. This contributed to the annual value of $76,000 for FY2017, which is 83.04% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Non Operating Investment Income of $76,000 as of FY2017, which was down 83.04% from $448,000 recorded in FY2016.
  • Over the past 5 years, Supernus Pharmaceuticals' Non Operating Investment Income peaked at $2.8 million during FY2014, and registered a low of -$13.4 million during FY2013.
  • Its 3-year average for Non Operating Investment Income is $239,000, with a median of $193,000 in 2015.
  • Its Non Operating Investment Income has fluctuated over the past 5 years, first crashed by 1,780.85% in 2013, then soared by 132.12% in 2016.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Non Operating Investment Income stood at -$13.4 million in 2013, then soared by 121.03% to $2.8 million in 2014, then slumped by 93.13% to $193,000 in 2015, then surged by 132.12% to $448,000 in 2016, then slumped by 83.04% to $76,000 in 2017.